Mark Elliott Boulding sold $409k of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 5,894 shares at an average of $69.33, traded Feb 17, 2026, filed Feb 19, 2026.
Score components
- +15RoleOfficer
- +16Trade size$409k at market
- 0Share of holdings soldSold 5.2% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578852-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | MOption exercise Common Stock10b5-1 | +2,813 | $25.69 | $72k | 114,125 | Feb 19, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -2,811 | $69.29 | $195k | 111,314 | Feb 19, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $70.13 | $140 | 111,312 | Feb 19, 2026 |
| Feb 18, 2026 | SOpen-market sale Common Stock10b5-1 | -3,081 | $69.36 | $214k | 108,231 | Feb 19, 2026 |
| Feb 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,813 | $0.00 | $0 | 22,501 | Feb 19, 2026 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 31Weak | PTC THERAPEUTICS, INC. | Matthew B. Klein CHIEF EXECUTIVE OFFICER | $171k 2,662 shares | -1% | |
| 40Moderate | PTC THERAPEUTICS, INC. | Stephanie Okey director | $1.1M 15,167 shares | -165% | |
| 43Moderate | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $253k 3,989 shares | -59% | |
| 35Weak | PTC THERAPEUTICS, INC. | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | $634k 10,000 shares | -11% | |
| 36Weak | PTC THERAPEUTICS, INC. | Stephanie Okey director | $401k 6,333 shares | -44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.